Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor
作者:Lyamin Z. Bendjeddou、Nadège Loaëc、Benoît Villiers、Eric Prina、Gerald F. Späth、Hervé Galons、Laurent Meijer、Nassima Oumata
DOI:10.1016/j.ejmech.2016.09.064
日期:2017.1
3,6-Disubstituted imidazo[1,2-b]pyridazine derivatives were synthesized to identify new inhibitors of various eukaryotic kinases, including mammalian and protozoan kinases. Among the imidazo[1,2-b]pyridazines tested as kinase inhibitors, several derivatives were selective for DYRKs and CLKs, with IC50 < 100 nM. The characterization of the kinome of several parasites, such as Plasmodium and Leishmania
Asymmetric Petasis Reactions Catalyzed by Chiral Biphenols
作者:Sha Lou、Scott E. Schaus
DOI:10.1021/ja8018934
日期:2008.6.1
Chiralbiphenolscatalyze the enantioselective Petasis reaction of alkenyl boronates, secondary amines, and ethyl glyoxylate. The reaction requires the use of 15 mol % of (S)-VAPOL as the catalyst, alkenyl boronates as nucleophiles, ethyl glyoxylate as the aldehyde component, and 3 A molecular sieves as an additive. The chiral alpha-amino ester products are obtained in good yields (71-92%) and high
Erythrina Alkaloid Analogues as nAChR Antagonists–A Flexible Platform for Leads in Drug Discovery
作者:Sebastian Clementson、Sergio Armentia Matheu、Emil Märcher Rørsted、Henrik Pedersen、Anders A. Jensen、Rasmus P. Clausen、Paulo Vital、Emil Glibstrup、Mikkel Jessing、Jesper L. Kristensen
DOI:10.1021/acs.joc.1c00707
日期:2021.6.18
Erythrina alkaloids and their centralnervoussystem effects have been studied for over a century, mainly due to their potent antagonistic actions at β2-containing nicotinic acetylcholine receptors (nAChRs). In the present work, we report a synthetic approach giving access to a diverse set of Erythrina natural product analogues and present the enantioselective total synthesis of (+)-Cocculine and (+)-Cocculidine
The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.
The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or/and syk inhibitors.